IPO market gets a boost as Medtronic-backed GI Dynamics gobbles $85m - UPDATE
This article was originally published in Clinica
GI Dynamics has raised Aus$80m ($85.2m) in an initial public offering on the Australian Stock Exchange, boosting hopes of an IPO recovery in the medtech market. The final amount was the minimum which the US company had hoped it would raise; it had allocated up to Aus$15m in oversubscriptions, according to its prospectus. Nonetheless, Aus$80m will still enable GI to be the largest float of the year so far in Australia. The company will be listed on 7 September under the ticker symbol GID, with a market value of Aus$304m.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.